Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Blood (2024) 143 (20): 2053–2058.

https://doi.org/10.1182/blood.2023021184

Published: 2024

Includes: Supplemental data

Journal Articles

Targeted Immunotherapy and Checkpoint Blockade in Children, Adolescents, and Young Adults with Lymphoma: Radical Hodgkin Cohort

Kayleigh Klose, Jessica Hochberg, Jaclyn Basso, Ana C. Xavier, Matthew J. Barth, Rodney R. Miles, Samir Kahwash, Stephan D. Voss, Suzanne Braniecki, Chitti Moorthy, Saro Armenian, Matthew J. Ehrhardt, Megan Lim, Lauren Harrison, Arvind Budhram, Ariel Stonberg, Stanton Goldman, Mitchell S. Cairo

Blood (2023) 142 (Supplement 1): 3083.

https://doi.org/10.1182/blood-2023-186691

Published: 2023

Journal Articles

Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine Combined with FAB Chemoimmunotherapy with Reduced Doxorubicin in CAYA with Mature De-Novo B-NHL

Anthony N. Audino, Stanton Goldman, Matthew J. Barth, Jessica Hochberg, Ana C. Xavier, Bruce Shiramizu, Qiuhu Shi, Lauren Harrison, Jackie Basso, Javier Oesterheld, Kenneth Matthew Heym, Richard A. Drachtman, Paul Harker-Murray, Sherrie L. Perkins, Rodney R. Miles, Mitchell S. Cairo

Blood (2023) 142 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2023-181756

Published: 2023

Journal Articles

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Blood (2022) 140 (Supplement 1): 6387–6389.

https://doi.org/10.1182/blood-2022-159694

Published: 2022

Journal Articles

Pilot Study Using Induction Chemo-Immunotherapy Followed By Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-Anaplastic T- or NK-Cell Lymphoma/Leukemia in Children, Adolescent, and Young Adults

Ana C. Xavier, Lauren Harrison, Rodney R. Miles, Stephan Voss, Megan S. Lim, Mitchell S. Cairo

Blood (2022) 140 (Supplement 1): 12029–12030.

https://doi.org/10.1182/blood-2022-160045

Published: 2022

Journal Articles

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Erin Guest, John Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J. Carroll, Nyla A. Heerema, Holly Kubaney, Amanda August, Melinda Pauly, Daniel Wechsler, Rodney R. Miles, Joel M. Reid, Cynthia Kihei, Lia Gore, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3256–3257.

https://doi.org/10.1182/blood-2022-167765

Published: 2022

Journal Articles

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Jessica C. Hochberg, MD, Stanton Goldman, MD, Matthew J. Barth, MD, Qiuhu Shi, PhD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Jackie Basso, Yaya Chu, PhD, Humayun Islam, Perry Gerard, MD MBA, FACR, Javier Oesterheld, MD, Kenneth Matthew Heym, MD, Ivan I. Kirov, MD, Richard A. Drachtman, MD, Paul Harker-Murray, MD PhD, Sherrie L. Perkins, MD PhD, Rodney R. Miles, MD PhD, Bruce Shiramizu, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139464

Published: 2020

Journal Articles

Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134730

Published: 2020

Journal Articles

The whole-genome landscape of Burkitt lymphoma subtypes

Blood (2019) 134 (19): 1598–1607.

https://doi.org/10.1182/blood.2019001880

Published: 2019

Includes: Supplemental data

Journal Articles

Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL)

Robert James Hayashi, Stuart S. Winter, MD, Kimberly P. Dunsmore, MD, Meenakshi Devidas, PhD, Brent Wood, MD PhD, Michelle L. Hermiston, MD PhD, David T Teachey, MD, Sherrie L. Perkins, MD PhD, Rodney R. Miles, MD PhD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Naomi Winick, MD, William L. Carroll, MD, Stephen P. Hunger, MD, Megan S. Lim, MD,PhD, Catherine M. Bollard, MD, Thomas G. Gross, MD PhD

Blood (2018) 132 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2018-99-113481

Published: 2018

Journal Articles

High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma

Thomas Ippolito, MSc, Rodney R. Miles, MD PhD, Vladimir Rodic, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2018) 132 (Supplement 1): 1586.

https://doi.org/10.1182/blood-2018-99-118932

Published: 2018

Journal Articles

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Blood (2017) 130 (16): 1819–1831.

https://doi.org/10.1182/blood-2017-02-767335

Published: 2017

Includes: Supplemental data

Journal Articles

miR-155 promotes FLT3-ITD–induced myeloproliferative disease through inhibition of the interferon response

Jared A. Wallace, Dominique A. Kagele, Anna M. Eiring, Carissa N. Kim, Ruozhen Hu, Marah C. Runtsch, Margaret Alexander, Thomas B. Huffaker, Soh-Hyun Lee, Ami B. Patel, Timothy L. Mosbruger, Warren P. Voth, Dinesh S. Rao, Rodney R. Miles, June L. Round, Michael W. Deininger, Ryan M. O’Connell

Blood (2017) 129 (23): 3074–3086.

https://doi.org/10.1182/blood-2016-09-740209

Published: 2017

Journal Articles

Targeting BET Bromodomains in Pre-Clinical Models of Burkitt Lymphoma

Thomas Ippolito, MS, Juan J Gu, PhD, Gregory Tang, Cory Mavis, MSc, Rodney R. Miles, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2016) 128 (22): 5381.

https://doi.org/10.1182/blood.V128.22.5381.5381

Published: 2016

Journal Articles

MiR-155 Promotes FLT3-ITD-Induced Myeloproliferative Disease through Inhibition of Interferon Signaling

Jared Wallace, Dominique Kagele, Ruozhen Hu, Marah Runtsch, Margaret Alexander, Thomas Huffaker, Timothy Mosbruger, Dinesh S. Rao, MD PhD, Rodney R. Miles, MD PhD, June Round, PhD, Ryan M. O'Connell, PhD

Blood (2016) 128 (22): 2853.

https://doi.org/10.1182/blood.V128.22.2853.2853

Published: 2016

Journal Articles

Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells

Rodney R. Miles, MD PhD, Vladimir Rodic, Matthew J. Barth, MD, Mitchell S. Cairo, MD, Michelle L. Hermiston, MD PhD

Blood (2016) 128 (22): 2944.

https://doi.org/10.1182/blood.V128.22.2944.2944

Published: 2016

Journal Articles

Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target

Blood (2016) 128 (22): 4095.

https://doi.org/10.1182/blood.V128.22.4095.4095

Published: 2016

Journal Articles

Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival

Shiven B. Patel, MD, Clinton C. Mason, PhD, Martha Glenn, MD, Christian N. Paxton, PhD, Sarah T. South, PhD, Melissa H. Cessna, MD, Julie D. Asch, MD, Erin F. Cobain, MD, Dale Bixby, MD PhD, Lauren B. Smith, MD, Shalini C. Reshmi, PhD, Julie M. Gastier-Foster, PhD, Joshua D. Schiffman, MD, Rodney R. Miles, MD PhD

Blood (2015) 126 (23): 1427.

https://doi.org/10.1182/blood.V126.23.1427.1427

Published: 2015

Journal Articles

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Timmy O'Connell, MS, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 5117.

https://doi.org/10.1182/blood.V126.23.5117.5117

Published: 2015

Journal Articles

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 4852.

https://doi.org/10.1182/blood.V126.23.4852.4852

Published: 2015

NARROW

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Targeted Immunotherapy and Checkpoint Blockade in Children, Adolescents, and Young Adults with Lymphoma: Radical Hodgkin Cohort

Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine Combined with FAB Chemoimmunotherapy with Reduced Doxorubicin in CAYA with Mature De-Novo B-NHL

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Pilot Study Using Induction Chemo-Immunotherapy Followed By Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-Anaplastic T- or NK-Cell Lymphoma/Leukemia in Children, Adolescent, and Young Adults

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

The whole-genome landscape of Burkitt lymphoma subtypes

Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL)

High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

miR-155 promotes FLT3-ITD–induced myeloproliferative disease through inhibition of the interferon response

Targeting BET Bromodomains in Pre-Clinical Models of Burkitt Lymphoma

MiR-155 Promotes FLT3-ITD-Induced Myeloproliferative Disease through Inhibition of Interferon Signaling

Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells

Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target

Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only